Pharmaceutical And Criminal Law#medical cannabis#AEMPS#Royal Decree 903/2025#hospital pharmacy#standardized preparations#CBD#home cultivation#compliance#registry

Medical Cannabis in Spain: Long-Awaited Regulation with Persistent Uncertainty

By Abogado Gentile8 min read

After years of debate, Royal Decree 903/2025 (October 7) opens regulated access to medical cannabis in Spain. It does not decriminalize or normalize cannabis; it channels use through a closed, hospital-based system strictly supervised by AEMPS, focused on specific clinical indications.

Purpose and eligible patients

Patients with spasticity due to multiple sclerosis, severe refractory epilepsy, chemotherapy-induced nausea and vomiting, or refractory chronic pain may access standardized preparations with defined THC/CBD composition, registered and controlled by AEMPS.

Access model: closed and hospital-only

  • Prescription: hospital specialist physicians only.
  • Dispensing: exclusively via hospital pharmacies (community pharmacies excluded).
  • Products: standardized extracts pre-authorized and registered.
  • This design permits medical use without liberalizing general access.

    What remains outside the law

    The decree does not change the general criminal status: home cultivation remains legally risky (potential CC 368); sale of CBD without health registration remains unlawful (administrative/customs sanctions); cannabis social clubs remain in a legal limbo without national regulation.

    Business implications

    A Registry of Standardized Cannabis Preparations enables authorized laboratories and operators to manufacture and distribute regulated extracts. Requirements include GMP, end-to-end traceability, periodic audits, and tight supply-chain control. Procedures before AEMPS are meticulous, and non-compliance may entail serious penalties or criminal liability.

    A dual, complex framework

    The rule entrenches a dual system: medical use under hospital control; recreational use prohibited and prosecuted; enterprise activity regulated within a highly technical compliance regime. In this landscape, specialized legal guidance is essential for patients, clinicians, and companies.

    Summary

    In short: RD 903/2025 opens medical access to standardized preparations under AEMPS but leaves home cultivation, unregistered CBD, and social clubs outside the legal perimeter. For businesses, the opportunity exists, conditioned on strict compliance (GMP, traceability, audits).

    Conclusion

    Abogado Gentile advises patients, clinicians, associations, and companies to operate lawfully, adapt to the new framework, and mitigate risk. If you need clarity on what the law permits or how to protect your project, book a consultation with our firm.